KIF21B

Across TCGA pan-cancer cohorts, KIF21B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIF21B data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher KIF21B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIF21B expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LSCC, HNSC, and GBM are the cancer types where KIF21B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.783	1.000	.035	9	view →
HNSC	OS	Median	All	0.270	1.000	.021	6	view →
GBM	DFS	Median	All	0.803	0.691	.042	2	view →
CCRCC	DFS	Median	III,IV	0.965	0.356	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KIF21B–LSCC (DFS)

Open the LSCC breakdown →